Form 4: Codexis CEO Granted 85,000 RSUs and 500,000 Stock Options

Codexis President and CEO Alison Moore was granted 85,000 restricted stock units and 500,000 stock options on November 13, 2025.

Summary

• Alison Moore, President and CEO of Codexis, Inc. (CDXS), acquired 85,000 shares of common stock in the form of restricted stock units (RSUs) on November 13, 2025.
• These RSUs vest as to one-third of the shares on each annual anniversary of the grant date, contingent on continued employment.
• Moore also acquired 500,000 stock options with an exercise price of $1.63 per share on November 13, 2025.
• The stock options vest and become exercisable for 25% of the shares on the first anniversary of the grant date, and 1/48th of the original number of shares monthly thereafter, also subject to continued employment.
• Following these transactions, Moore beneficially owns 254,332 shares of common stock and 500,000 derivative securities (stock options).
• The filing was signed by Georgia Erbez, as Attorney-in-Fact for Alison Moore, on November 17, 2025, under a Power of Attorney dated October 13, 2025.

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation event involving equity grants, which is generally positive for aligning management incentives with shareholder interests, but does not contain new operational or financial performance data.

Positives

• The grant of 85,000 restricted stock units and 500,000 stock options to the President and CEO aligns management's incentives with long-term shareholder value creation.
• The vesting schedules for both the RSUs (one-third annually) and stock options (25% after one year, then monthly) promote retention of key leadership.

Risks

• The vesting of both restricted stock units and stock options is subject to the Reporting Person's continued employment, meaning the benefits are contingent on her remaining with the company.

Future Outlook

The grants of equity awards with multi-year vesting schedules indicate an expectation of continued leadership and performance from the CEO, aligning her long-term interests with the company's future success.

Industry Context

Equity grants to executive leadership are a standard practice in the biotechnology and specialty chemicals industries, aiming to incentivize performance and retain key talent. The size and structure of these grants are typically benchmarked against peer companies to ensure competitive compensation.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a CEO is a common compensation practice across the biotechnology and specialty chemicals sectors, similar to companies like Amyris, Inc. or Ginkgo Bioworks Holdings, Inc., which frequently use equity to attract and retain top talent.
• The vesting schedule for RSUs (one-third annually over three years) and stock options (25% after one year, then monthly over four years) is typical for executive equity awards, designed to promote long-term retention and align executive interests with shareholder value creation over several years.
• The exercise price of $1.63 for the stock options would be compared to the company's stock price on the grant date to assess if it was at-the-money, in-the-money, or out-of-the-money, which is a standard evaluation metric for option grants in the industry.

Corporate Governance

Related Party Transactions

• The equity grants to the CEO are a form of related party transaction (compensation to an executive), which is standard practice and disclosed as required.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's financial interests with long-term shareholder value, potentially leading to more focused strategic decisions aimed at stock price appreciation.
• Employees: The grants demonstrate the company's commitment to executive retention and performance-based compensation, which can set a precedent for other employees.

Next Steps

• Alison Moore will continue to hold her position as President and CEO, with her equity awards vesting over the coming years subject to continued employment.
• The company will continue to report any changes in beneficial ownership for its insiders via subsequent Form 4 filings.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (equity grants) and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily indicates that the CEO's incentives are aligned with long-term company performance.

Keywords

Codexis, CDXS, Alison Moore, CEO, Stock Grant, Restricted Stock Units, RSU, Stock Options, Insider Transaction, Executive Compensation, SEC Form 4